Respiratory Syncytial Virus Prevention New Drug Approved for Clinical Use

Recently, the Class I new drug SIBP-A16 injection developed by China Biotechnology Institute of China National Pharmaceutical Group Shanghai Bioproducts Research Institute has obtained the clinical trial approval notification from the National Medical Products Administration. It is intended for the prevention of lower respiratory tract infections caused by respiratory syncytial virus. As a RSV prevention antibody drug, the approval of SIBP-A16 represents a comprehensive upgrade of China's biopreventive antibody research and development system, and also holds the promise of providing a new specific immune prevention choice for RSV protection in infants and young children in China in the future.